Show simple item record

dc.contributor.authorTimbrell, Simon
dc.contributor.authorAglan, Hosam
dc.contributor.authorCramer, Angela
dc.contributor.authorFoden, Phil
dc.contributor.authorWeaver, David
dc.contributor.authorPachter, Jonathan
dc.contributor.authorKilgallon, Aoife
dc.contributor.authorClarke, Robert B
dc.contributor.authorFarnie, Gillian; email: gillian.farnie@ndorms.ox.ac.uk
dc.contributor.authorBundred, Nigel J; orcid: 0000-0001-6007-056X; email: bundredn@manchester.ac.uk
dc.date.accessioned2021-06-30T01:20:24Z
dc.date.available2021-06-30T01:20:24Z
dc.date.issued2021-05-28
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625088/article.pdf?sequence=2
dc.identifier.citationNPJ breast cancer, volume 7, issue 1, page 65
dc.identifier.urihttp://hdl.handle.net/10034/625088
dc.descriptionFrom Europe PMC via Jisc Publications Router
dc.descriptionHistory: ppub 2021-05-01, epub 2021-05-28
dc.descriptionPublication status: Published
dc.description.abstractCancer stem-like cells (CSC) contribute to therapy resistance and recurrence. Focal adhesion kinase (FAK) has a role in CSC regulation. We determined the effect of FAK inhibition on breast CSC activity alone and in combination with adjuvant therapies. FAK inhibition reduced CSC activity and self-renewal across all molecular subtypes in primary human breast cancer samples. Combined FAK and paclitaxel reduced self-renewal in triple negative cell lines. An invasive breast cancer cohort confirmed high FAK expression correlated with increased risk of recurrence and reduced survival. Co-expression of FAK and CSC markers was associated with the poorest prognosis, identifying a high-risk patient population. Combined FAK and paclitaxel treatment reduced tumour size, Ki67, ex-vivo mammospheres and ALDH+ expression in two triple negative patient derived Xenograft (PDX) models. Combined treatment reduced tumour initiation in a limiting dilution re-implantation PDX model. Combined FAK inhibition with adjuvant therapy has the potential to improve breast cancer survival.
dc.languageeng
dc.rightsLicence for this article: cc by
dc.sourceissn: 2374-4677
dc.sourceessn: 2374-4677
dc.sourcenlmid: 101674891
dc.titleFAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity.
dc.typearticle
dc.date.updated2021-06-30T01:20:24Z


Files in this item

Thumbnail
Name:
article.pdf
Size:
7.353Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record